<ydktm class="hqvrw"></ydktm>

南宫NG28基因

Be the most trusted biotech company

2025-04-01

Henlius to Present Three Preclinical Studies at AACR 2025
2025-03-28

European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11
2025-03-27

Latest RWS Results of Serplulimab for SCLC Released at 2025 ELCC
2025-03-26

First Japanese Patient Dosed in Phase 3 MRCT of Dual HER2 Blockade Therapy for HER2+ GC
2025-03-25

Henlius Announces China’s NMPA Approval of Phase 2 Clinical Trial for HLX79 Plus HANLIKANG in Active Glomerulonephritis
2025-03-24

Henlius 2024 Annual Results: Steady Revenue Growth with a Net Profit of RMB820.5 million, Up by 50.3% YoY
2025-03-19

Henlius Receives Orphan-Drug Designation for HLX22(Innovative anti-HER2 mAb) in the U.S. for Gastric Cancer
2025-03-05

Henlius Successfully Holds First In-Person Investigator Meeting in Japan, Accelerating Global Clinical Research for Innovative Pipeline
2025-02-26

Updated Long-term Survival Results from the International Multicenter Phase 3 Clinical Trial of HANQUYOU Published in The Breast